To evaluate the vaccine, Dr. Convit and his team apply the immunotherapy against leishmaniasis in 11532 patients with American Cutaneous Leishmaniasis in Venezuela, and observe a mean of 95.7% of cured patients. They publish an article with these results, and based on this success, the immunotherapy is applied in other countries of the region to treat patients with Cutaneous Leishmaniasis.

Terms of Use          Privacy Policy